For most men with stage 1 prostate cancer, active surveillance is the recommended first-line approach, not immediate surgery or radiation. That may sound counterintuitive, but stage 1 tumors are slow-growing, confined entirely to the prostate, and carry a 10-year survival rate of 100% across all age groups. The goal is to avoid the side effects of treatment unless monitoring shows the cancer is becoming more aggressive.
That said, active surveillance isn’t the right fit for everyone. Your age, overall health, family history, and personal comfort with monitoring all factor into the decision. Here’s what each option actually involves.
What Stage 1 Means
Stage 1 prostate cancer is defined by three criteria: a PSA level below 10, a Gleason score of 6 or less (Grade Group 1), and a tumor that’s either too small to feel on a physical exam or takes up no more than half of one side of the prostate. The cancer hasn’t spread to lymph nodes or anywhere else in the body. This places it firmly in the low-risk category under both the American Urological Association and NCCN guidelines.
Why Active Surveillance Is the Standard
Active surveillance means your cancer is monitored closely but not treated right away. You’ll typically get PSA blood tests every 3 to 6 months in the first year or two, plus an MRI-guided biopsy about a year after diagnosis. After that initial stretch, the schedule depends on your situation. A healthy man in his 50s will generally continue with regular PSA checks and periodic biopsies on a similar timeline. A man in his 70s with other health conditions may only need testing every few years or when symptoms appear.
The logic is straightforward: stage 1 prostate cancer grows slowly enough that many men will never need treatment at all. Monitoring catches the minority of cases where the cancer starts to change, and treatment can begin at that point without any lost ground. Both the AUA and NCCN recommend active surveillance as the preferred approach for low-risk and very-low-risk prostate cancer.
There are situations where immediate treatment makes more sense even at stage 1. A strong family history of aggressive prostate cancer, urinary symptoms the tumor is causing, or significant anxiety about living with untreated cancer are all legitimate reasons to consider surgery or radiation from the start.
Genomic Tests Can Help You Decide
If you’re uncertain whether to monitor or treat, genomic tests can add a layer of information beyond PSA and Gleason scores. These tests analyze the genetic activity of your tumor tissue to estimate how likely it is to become aggressive. Three are commonly used: Prolaris estimates the risk of dying from prostate cancer within 10 years if it’s managed conservatively. Oncotype DX predicts whether the tumor has features that look more dangerous under a microscope than the biopsy suggested. Decipher produces a score from 0 to 1, where each 0.1 increase represents a 10% jump in the risk of the cancer eventually spreading.
These tests change treatment decisions in a meaningful number of cases. In one study, Oncotype DX results disagreed with the standard risk category nearly 40% of the time, and 18% of patients had their recommendation switched between surveillance and active treatment as a result. Prolaris results led to a change in the treatment plan roughly a third of the time. If your doctor hasn’t mentioned genomic testing, it’s worth asking about.
Surgery: What to Expect
Radical prostatectomy removes the entire prostate gland along with some surrounding tissue. The most common technique today is robot-assisted laparoscopic surgery, where a surgeon operates through several small incisions in the lower abdomen using robotic instruments. Compared to traditional open surgery (one large incision), the robotic approach results in less blood loss, less pain, a shorter hospital stay, and faster recovery.
Most men go home 1 to 2 days after surgery and return to their normal routine within 4 to 6 weeks. During that recovery period, you’ll need to avoid lifting anything over 10 pounds and skip activities involving bending, pushing, or twisting.
When possible, surgeons use a nerve-sparing technique to preserve the nerves running alongside the prostate that control erections. Even with nerve-sparing surgery, side effects are common. At 5 years after surgery, about 15% of men experience ongoing urinary incontinence (frequent leaking or no control), and roughly 79% report erectile dysfunction significant enough to prevent intercourse. These numbers are important to weigh, especially since stage 1 cancer is unlikely to be life-threatening regardless of which path you choose.
Radiation: Two Main Approaches
External beam radiation therapy delivers targeted radiation to the prostate from outside the body, typically over the course of several weeks with daily sessions. Brachytherapy takes a different approach: small radioactive seeds are implanted directly into the prostate, delivering radiation from the inside. Both are effective for localized prostate cancer.
Radiation generally causes fewer urinary problems than surgery. At 5 years, only about 4% of men treated with external beam radiation had significant incontinence, compared to 15% after surgery. Erectile dysfunction was also less common with radiation at the 2-year mark (50% versus 82% for surgery), though by 5 years the gap narrowed somewhat (64% versus 79%).
Brachytherapy shows a slight edge over external beam radiation for sexual function in the weeks right after treatment, but that difference fades. By 3 months, and out to at least 2 years, sexual function outcomes are comparable between the two. Some research suggests brachytherapy alone may offer better 5-year disease control for low-risk patients, with fewer gastrointestinal side effects, though the evidence isn’t entirely settled.
Focal Therapies: HIFU and Cryotherapy
Newer approaches aim to treat just the cancerous part of the prostate rather than the whole gland. High-intensity focused ultrasound (HIFU) uses concentrated sound waves to heat and destroy tumor tissue. Cryotherapy freezes it. Both are considered organ-sparing alternatives for men with low-risk disease who want to avoid the side effects of removing or radiating the entire prostate.
Continence outcomes are encouraging. About 89% of men treated with HIFU and 89% treated with cryotherapy maintained urinary control, similar to the 88% rate after robotic surgery in one prospective study. Erectile function is a different story: only 44% of HIFU patients recovered sexual function, and 55% reported no erections at follow-up.
The bigger concern is durability. In the same study, HIFU showed earlier treatment failures than surgery, with a median time to failure of just 8 months. About three-quarters of recurrences after focal therapy happened within the area that was already treated, suggesting the initial ablation didn’t fully eliminate the cancer. Robotic surgery had the lowest complication rate (under 3%) compared to 20% for HIFU and 32% for cryotherapy. Focal therapies remain an active area of development, but they aren’t yet considered the standard of care for most patients.
Comparing the Trade-Offs
- Active surveillance preserves quality of life entirely but requires ongoing monitoring and the psychological weight of knowing cancer is present. Some men eventually need treatment if the cancer progresses.
- Surgery removes the cancer completely and eliminates uncertainty, but carries the highest rates of incontinence and erectile dysfunction. Recovery takes 4 to 6 weeks.
- Radiation avoids surgery and has lower rates of urinary side effects, but treatment stretches over weeks (for external beam) and still affects sexual function in the majority of men.
- Focal therapies spare most of the prostate and preserve continence well, but have higher complication rates than surgery and less proven long-term durability.
For a man with stage 1 prostate cancer, there is no single “best” treatment in a universal sense. The survival rate is essentially the same regardless of approach. What differs are the side effects you’re willing to accept, how you feel about ongoing monitoring, and how your age and overall health shape the risk-benefit calculation. A genomic test can help clarify whether your particular tumor is one that’s safe to watch or one that warrants early action.